Xenon Pharmaceuticals Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Unless otherwise stated, amounts are U.S. dollars; financial statement figures are in millions.
Business context
Xenon is a clinical-stage biopharmaceutical company focused on neurological disorders, particularly epilepsy. It has no product-sales revenue; reported revenue comes from collaborations and licensing. Key programs include proprietary XEN1101 and XEN496 and partnered NBI-921352 and PCRX301.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / prior balance |
|---|---|---|
| Revenue | $8.8 million | $4.4 million |
| Research and development expense | $19.4 million | $16.3 million |
| General and administrative expense | $6.8 million | $4.1 million |
| Operating loss | $17.4 million | $16.1 million |
| Net loss | $19.7 million | $15.8 million |
| Net loss per common share | $0.35 | $0.42 |
| Operating cash used | $18.4 million | $20.7 million |
| Cash and cash equivalents | $116.5 million | $175.7 million at Dec. 31, 2021 |
| Marketable securities | $421.4 million | $376.1 million at Dec. 31, 2021 |
Cash, cash equivalents and marketable securities totaled $537.9 million at quarter-end. The company reported total assets of $558.1 million and total liabilities of $16.2 million, including an $8.2 million long-term operating lease liability. No material debt financing was outstanding. Gross margin is not applicable to the reported collaboration-revenue model.
Revenue increased 101% year over year, mainly reflecting $7.1 million of recognized Neurocrine milestone revenue and $1.6 million of Neurocrine services and transaction-price revenue. Q1 2021 included a $3.0 million Pacira milestone. R&D rose 19%, principally due to internal discovery programs and XEN1101; G&A rose 65%, including higher stock-based compensation, staffing and recruitment costs. Net loss widened by $3.9 million, partly due to a $3.4 million unrealized loss on marketable securities as market yields changed.
Investing activities used $48.9 million, largely reflecting net purchases of marketable securities; financing activities provided $7.9 million, primarily from Neurocrine’s share purchase. Cash and cash equivalents fell by $59.1 million, while marketable securities increased. The company stated that cash and cash equivalents plus marketable securities were expected to fund operating and capital requirements for at least 12 months from the report date, based on assumptions that could prove incorrect.
Outlook, developments and risks
- Management expects significant expenses and operating losses for the foreseeable future, with R&D remaining the largest expense category for at least the next 12–24 months. Product-sales revenue is not expected for several years, if ever; near-term revenue depends substantially on collaborations and milestone timing.
- XEN1101: following positive Phase 2b X-TOLE results announced in 2021, Xenon planned an FDA end-of-Phase-2 meeting in Q2 2022 and estimated starting a Phase 3 focal-epilepsy program in the second half of 2022. X-NOVA MDD topline results were anticipated in 2023.
- XEN496: the EPIK Phase 3 study in pediatric KCNQ2-DEE was ongoing, with completion anticipated in 2023. Patient recruitment and trial-site initiation may be affected by COVID-19 and the small target population.
- Neurocrine was conducting Phase 2 studies of NBI-921352, with data expected in 2023. Xenon may receive up to $1.67 billion in additional development, regulatory and sales milestones under the collaboration, plus royalties; amounts are contingent and not assured.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, patient enrollment, reliance on collaborators and third-party manufacturers/CROs, intellectual-property protection, and the need for future financing. The company had a $250 million ATM facility, with no shares sold under it by March 31, 2022. Future equity issuance could dilute shareholders.
- Other disclosed items: the remaining 1,016,000 preferred shares converted one-for-one into common shares in March 2022; 2.8 million pre-funded warrants remained unexercised. Xenon had a $2.8 million unsatisfied Medpace service commitment, with no liability recorded because it intended to use Medpace services. Management reported no material legal proceedings and concluded disclosure controls were effective.
Important facts for investors to verify
- Progress and final data from XEN1101, XEN496 and Neurocrine’s NBI-921352 trials, including whether stated timelines remain achievable.
- Actual operating cash use, investment balances and runway against the 12-month liquidity estimate, particularly as development spending rises.
- Timing and accounting of collaboration milestones, and the extent to which future revenue depends on partner decisions and trial outcomes.
- Potential dilution from the ATM, outstanding options and pre-funded warrants, and any additional financing needs.
- Effects of market yields, foreign-exchange movements, inflation and COVID-19 on investment values, costs and clinical operations.